 Carrie Marshall
Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 5 | 2024 | 346 | 1.040 |
Why?
| | Central Nervous System Neoplasms | 1 | 2022 | 173 | 0.600 |
Why?
| | Cytological Techniques | 1 | 2017 | 28 | 0.530 |
Why?
| | Observer Variation | 2 | 2017 | 353 | 0.520 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 59 | 0.510 |
Why?
| | Thyroid Nodule | 3 | 2024 | 56 | 0.450 |
Why?
| | Biopsy, Fine-Needle | 3 | 2019 | 70 | 0.400 |
Why?
| | Pathology, Molecular | 1 | 2012 | 25 | 0.370 |
Why?
| | Mediastinum | 1 | 2011 | 23 | 0.340 |
Why?
| | Lymphoproliferative Disorders | 1 | 2011 | 54 | 0.330 |
Why?
| | Pancreatic Neoplasms | 1 | 2017 | 931 | 0.290 |
Why?
| | Biomarkers, Tumor | 5 | 2025 | 1330 | 0.280 |
Why?
| | Lymph Nodes | 1 | 2011 | 505 | 0.270 |
Why?
| | Osteochondroma | 1 | 2025 | 10 | 0.230 |
Why?
| | Nose Neoplasms | 1 | 2025 | 26 | 0.230 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2025 | 31 | 0.230 |
Why?
| | Hamartoma | 1 | 2025 | 28 | 0.230 |
Why?
| | Thyroglobulin | 1 | 2024 | 30 | 0.210 |
Why?
| | Diagnosis, Differential | 5 | 2025 | 1503 | 0.210 |
Why?
| | Adamantinoma | 1 | 2023 | 3 | 0.210 |
Why?
| | Thyroidectomy | 1 | 2024 | 91 | 0.200 |
Why?
| | Carcinoma | 2 | 2017 | 231 | 0.200 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1181 | 0.200 |
Why?
| | Bronchoscopy | 2 | 2016 | 227 | 0.180 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1496 | 0.180 |
Why?
| | Tissue Scaffolds | 1 | 2024 | 222 | 0.180 |
Why?
| | Paraneoplastic Syndromes | 1 | 2021 | 12 | 0.180 |
Why?
| | Motor Neuron Disease | 1 | 2021 | 21 | 0.180 |
Why?
| | Surgical Wound Infection | 1 | 2024 | 330 | 0.170 |
Why?
| | Laboratories | 2 | 2019 | 111 | 0.170 |
Why?
| | Bone Neoplasms | 1 | 2023 | 252 | 0.170 |
Why?
| | Orthopedic Procedures | 1 | 2023 | 233 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2024 | 1127 | 0.160 |
Why?
| | Pheochromocytoma | 1 | 2021 | 58 | 0.160 |
Why?
| | Paraganglioma | 1 | 2021 | 53 | 0.160 |
Why?
| | Extracellular Matrix | 1 | 2024 | 564 | 0.160 |
Why?
| | Spine | 1 | 2022 | 181 | 0.160 |
Why?
| | Hodgkin Disease | 1 | 2021 | 168 | 0.150 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2022 | 230 | 0.150 |
Why?
| | Central Nervous System | 1 | 2022 | 272 | 0.150 |
Why?
| | Neuroendocrine Tumors | 1 | 2021 | 112 | 0.150 |
Why?
| | Carcinoma, Papillary | 3 | 2017 | 80 | 0.150 |
Why?
| | Pathology | 1 | 2019 | 21 | 0.150 |
Why?
| | Pathology, Clinical | 2 | 2017 | 29 | 0.150 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 210 | 0.150 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2640 | 0.150 |
Why?
| | Trans-Activators | 1 | 2021 | 398 | 0.140 |
Why?
| | Mutation | 3 | 2022 | 4120 | 0.140 |
Why?
| | Transcriptome | 3 | 2021 | 1049 | 0.140 |
Why?
| | Smokers | 1 | 2018 | 148 | 0.130 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 141 | 0.130 |
Why?
| | Histocytochemistry | 1 | 2017 | 79 | 0.130 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2017 | 41 | 0.130 |
Why?
| | Middle Aged | 9 | 2024 | 35730 | 0.120 |
Why?
| | Cytodiagnosis | 1 | 2016 | 31 | 0.120 |
Why?
| | Image-Guided Biopsy | 1 | 2016 | 41 | 0.120 |
Why?
| | Optic Nerve | 1 | 2016 | 65 | 0.120 |
Why?
| | Aged, 80 and over | 4 | 2019 | 8152 | 0.120 |
Why?
| | Precision Medicine | 1 | 2019 | 457 | 0.110 |
Why?
| | Humans | 20 | 2025 | 144221 | 0.110 |
Why?
| | Aged | 8 | 2024 | 25674 | 0.110 |
Why?
| | Reproducibility of Results | 4 | 2019 | 3401 | 0.110 |
Why?
| | Ultrasonography, Interventional | 1 | 2016 | 160 | 0.100 |
Why?
| | Male | 10 | 2025 | 71752 | 0.100 |
Why?
| | Alphapapillomavirus | 1 | 2014 | 36 | 0.100 |
Why?
| | Endosonography | 2 | 2016 | 157 | 0.100 |
Why?
| | Female | 12 | 2025 | 77792 | 0.100 |
Why?
| | Head and Neck Neoplasms | 1 | 2018 | 560 | 0.100 |
Why?
| | Spinal Cord | 1 | 2016 | 381 | 0.100 |
Why?
| | ErbB Receptors | 2 | 2016 | 627 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 1986 | 0.100 |
Why?
| | Neoplasms | 2 | 2019 | 2914 | 0.090 |
Why?
| | Glioblastoma | 1 | 2016 | 350 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1826 | 0.090 |
Why?
| | CD5 Antigens | 1 | 2011 | 10 | 0.090 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2011 | 23 | 0.080 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 43 | 0.080 |
Why?
| | Receptors, IgE | 1 | 2011 | 44 | 0.080 |
Why?
| | Adult | 8 | 2024 | 40228 | 0.080 |
Why?
| | CD3 Complex | 1 | 2011 | 110 | 0.080 |
Why?
| | Immunophenotyping | 1 | 2011 | 327 | 0.080 |
Why?
| | Papillomavirus Infections | 1 | 2014 | 354 | 0.080 |
Why?
| | Lung Diseases | 1 | 2016 | 795 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1950 | 0.070 |
Why?
| | Prospective Studies | 2 | 2019 | 7910 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2011 | 1193 | 0.060 |
Why?
| | Kidney Diseases, Cystic | 1 | 2006 | 24 | 0.060 |
Why?
| | Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2025 | 2 | 0.060 |
Why?
| | Hyphae | 1 | 2024 | 11 | 0.060 |
Why?
| | Diaphyses | 1 | 2023 | 13 | 0.050 |
Why?
| | Ulna | 1 | 2023 | 35 | 0.050 |
Why?
| | Fibula | 1 | 2023 | 36 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1463 | 0.050 |
Why?
| | Fungi | 1 | 2024 | 161 | 0.050 |
Why?
| | Prognosis | 2 | 2024 | 4221 | 0.050 |
Why?
| | Preoperative Care | 1 | 2024 | 376 | 0.040 |
Why?
| | Wound Healing | 1 | 2024 | 361 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2021 | 306 | 0.040 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2021 | 90 | 0.040 |
Why?
| | Lung Diseases, Interstitial | 1 | 2006 | 664 | 0.040 |
Why?
| | Pre-Analytical Phase | 1 | 2019 | 1 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 766 | 0.040 |
Why?
| | United States | 4 | 2019 | 15642 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 944 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 16803 | 0.040 |
Why?
| | Singapore | 1 | 2019 | 26 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 212 | 0.040 |
Why?
| | Accreditation | 1 | 2019 | 98 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 39 | 0.030 |
Why?
| | Cetuximab | 1 | 2018 | 113 | 0.030 |
Why?
| | Phthalazines | 1 | 2018 | 64 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 408 | 0.030 |
Why?
| | Adolescent | 3 | 2025 | 22281 | 0.030 |
Why?
| | Thyroid Gland | 1 | 2017 | 83 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2024 | 11501 | 0.030 |
Why?
| | X-linked Nuclear Protein | 1 | 2016 | 8 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2017 | 309 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 704 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 394 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1266 | 0.030 |
Why?
| | Societies, Medical | 1 | 2019 | 865 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3561 | 0.030 |
Why?
| | PTEN Phosphohydrolase | 1 | 2016 | 166 | 0.030 |
Why?
| | DNA Helicases | 1 | 2016 | 145 | 0.030 |
Why?
| | Papanicolaou Test | 1 | 2014 | 35 | 0.030 |
Why?
| | Breast Neoplasms | 1 | 2007 | 2502 | 0.030 |
Why?
| | Vaginal Smears | 1 | 2014 | 56 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2541 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2097 | 0.020 |
Why?
| | Biomedical Research | 1 | 2019 | 714 | 0.020 |
Why?
| | Apoptosis | 1 | 2021 | 2450 | 0.020 |
Why?
| | Risk | 1 | 2014 | 902 | 0.020 |
Why?
| | Child | 2 | 2025 | 22491 | 0.020 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2014 | 275 | 0.020 |
Why?
| | Nuclear Proteins | 1 | 2016 | 751 | 0.020 |
Why?
| | Child, Preschool | 1 | 2025 | 11656 | 0.020 |
Why?
| | Histones | 1 | 2016 | 656 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2016 | 1183 | 0.020 |
Why?
| | Mastectomy, Modified Radical | 1 | 2007 | 6 | 0.020 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2007 | 36 | 0.020 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2007 | 69 | 0.020 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2007 | 221 | 0.020 |
Why?
| | Tamoxifen | 1 | 2007 | 218 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 3842 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 6031 | 0.010 |
Why?
| | Lung | 1 | 2016 | 4158 | 0.010 |
Why?
| | Young Adult | 1 | 2019 | 13949 | 0.010 |
Why?
|
|
Marshall's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|